PATENT

Docket No. 2016-4010US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Jason D. Bannan et al.

Serial No.

09/335,581

Group Art Unit: 1645

Filed

June 18, 1999

Examiner: N.M. Minnifield

For

PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC SHOCK

SYNDROME AND SEPTIC SHOCK

AMENDMENT FEE TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment Pursuant to 37 C.F.R. 1.111 for the above-identified application.

[X] No additional fee is required.

The additional fee has been calculated as shown below: []

CLAIMS AS AMENDED

	Claims Remaining After Amendment	C P	lighest No. Covered by Trevious Tayments	Present Extra	Rate	Additional Fee
Total*						
Claims	36	-	76	= 0	x \$18.00	\$ <u>-0-</u>
Independent						
Claims	4	-	13	= 0	x \$80.00	\$ <u>-0-</u>
Multiple	(If claims added	•				
Dependent Claim(s)	Multiple Depend was not Multiple in application be	Depende	ent Claims(s)			\$ <u>-0-</u>
	\$260.00 to additi				Tot	al: \$ <u>-0-</u>
[] Statem	ent of "Small Entity	y" Status	Under 37 CFR	k § 1.27 filed		
	ed Fees Under 37 CFR § 1.9(f) (50% of total) paid herewith.					\$

Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. § 1.75(c).

Docket No. <u>2026-4010US2</u>

[]	Charge fee to Deposit Account No. 13-4500. Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.						
[X]	The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, including all fees pursuant to 37 C.F.R. § 1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2016-4010US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.						
[]	Page(s) of substitute Sequence Listing						
[]	Computer disk(s) containing substitute Sequence Listing						
[]	Statement under 37 C.F.R. § 1.825(b) that the computer and paper copies of the substitute Sequence Listin are the same.						
[]	A check in the amount of \$ to cover the filing fee is attached.						
	Respectfully submitted,						
	MORGAN & FINNEGAN, L.L.P.						
Dated:	October 12, 2000 By: Mary J. Morry Registration No. 34,398						

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile

FORM: AMD-TRAN.NY

Rev. 11/13/98



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :

Jason D. Bannan et al.

Serial No.

09/335,581

Group Art Unit: 1645

Filed

June 18, 1999

Examiner: N.M. Minnifield

For

PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC

SHOCK SYNDROME AND SEPTIC SHOCK

AMENDMENT UNDER 37 CFR §1.111 IN RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed September 12, 2000 subjecting the pending claims to a restriction/election requirement.

AMENDMENTS

Please amend the inventorship designation to delete Kumar Visvanathan as a named inventor.

Please cancel claims 4 to 6, 8 and 11 to 49 without prejudice.

Please add the following new claims:

- 50. A peptide comprising a consensus amino acid sequence CMYGGX₁TX₂HX₄GN (SEQ ID NO: 30) wherein X_1 is selected from the group consisting of V and I; X_2 is selected from the group consisting of L, E, K, P and N and wherein X_4 is selected from the group consisting of D, N, E, Q and H.
 - 51. A peptide of claim 50 wherein X_1 is V.

572897_1